Edgewood Management LLC Vertex Pharmaceuticals Inc Transaction History

Edgewood Management LLC

$37.1 Billion
Q3 2024

A detailed history of Edgewood Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Edgewood Management LLC holds 1,546,370 shares of VRTX stock, worth $614 Million. This represents 1.94% of its overall portfolio holdings.

Number of Shares

1,546,370

Previous 19,387 7876.32%

Holding current value

$614 Million

Previous $9.09 Million 7814.44%

% of portfolio

1.94%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$460.0 - $505.78 $702 Million - $772 Million	1,526,983 Added 7876.32%	1,546,370 $719 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $433,374 - $474,183	-1,063 Reduced 5.2%	19,387 $8.1 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $571,520 - $642,960	2,000 Added 10.84%	20,450 $5.91 Million
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $1.54 Million - $1.72 Million	-5,638 Reduced 23.41%	18,450 $5.34 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $2.72 Million - $3.04 Million	-15,000 Reduced 38.37%	24,088 $4.37 Million
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $555,131 - $728,259	-2,462 Reduced 5.93%	39,088 $11.3 Million
Q1 2020 May 13, 2020	SELL	$199.77 - $247.81 $1.02 Million - $1.26 Million	-5,100 Reduced 10.93%	41,550 $9.89 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $1.94 Million - $2.61 Million	11,650 Added 33.29%	46,650 $10.2 Million
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $500,128 - $584,351	-3,299 Reduced 8.61%	35,000 $5.7 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $5.67 Million - $6.21 Million	38,299	38,299 $5.82 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgewood Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Edgewood Management LLC with notifications on news.

Account

Edgewood Management LLC Vertex Pharmaceuticals Inc Transaction History